2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156155
    GYS1-IN-1 2839916-15-1 98%
    GYS1-IN-1 (compound 783) is a glycogen synthase 1(GYS1) inhibitor. GYS1-IN-1 can be used for the study of GYS1 -mediated disease, such as Gaucher and Fabry diseases.
    GYS1-IN-1
  • HY-156208
    C2 Adamantanyl galactosylceramide (d18:1/2:0) 574738-16-2
    C2 Adamantanyl galactosylceramide (AdaGalCer) (d18:1/2:0) is a bioactive sphingolipid. C2 Adamantanyl galactosylceramide (d18:1/2:0) stimulates glucocerebrosidase activity in vitro. C2 Adamantanyl galactosylceramide (d18:1/2:0) inhibits microsomal LacCer and Gb3 synthase, and inhibits cell sulfatide synthesis. C2 Adamantanyl galactosylceramide (d18:1/2:0) reduces glucosylceramide (GlcCer) levels in normal and lysosomal storage disease (LSD) cells. C2 Adamantanyl galactosylceramide (d18:1/2:0) acts as a substrate for A4GALT and is able to lower Gb3 levels with an IC50 concentration of 40 μM in fabry disease cells.
    C2 Adamantanyl galactosylceramide (d18:1/2:0)
  • HY-156240
    DI-1548 2247060-97-3 98%
    DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 (IC50 = 4.6 nM). DI-1548 potently and selectively inhibits cullin 3 neddylation at nanomolar concentrations, and exhibits no obvious effect on the neddylation of other cullin members (including cullin 1, 2, 4A, 4B, and 5). DI-1548 exhibits no cytotoxicity. DI-1548 covalently binds to DCN1, disrupting the DCN1-UBC12 interaction, causing the collapse of the neddylation complex, inactivating CRL3, leading to NRF2 accumulation and upregulation of its target genes, and ultimately protecting mice from liver damage. DI-1548 can be used in liver injury research.
    DI-1548
  • HY-156380
    α-Amylase/α-Glucosidase-IN-6 98%
    α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities.
    α-Amylase/α-Glucosidase-IN-6
  • HY-156405
    FTO-IN-10 98%
    FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC50 of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells.
    FTO-IN-10
  • HY-156447
    α-Glucosidase-IN-40 98%
    α-Glucosidase-IN-40 (compound 5) is a noncompetitive α-glucosidase enzyme inhibitor with an IC50 of 24.62 μM.
    α-Glucosidase-IN-40
  • HY-156558
    SeGalNac 1365541-49-6 98%
    SeGalNac is a selenium metabolite found in human urine. SeGalNac can be used in the study of selenoglucose metabolism.
    SeGalNac
  • HY-15656B
    Ceritinib mesylate 2055376-74-2 98%
    Ceritinib (LDK378) mesylate is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib mesylate also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib mesylate shows great antitumor potency.
    Ceritinib mesylate
  • HY-156624
    Lingdolinurad 2088176-96-7 98%
    Lingdolinurad is urate transporter inhibitor, targeting to hURAT1.Lingdolinurad can be used for research in hyperuricemia in vitro and in vivo.
    Lingdolinurad
  • HY-156648
    Vamagloxistat 2408241-62-1 98%
    Vamagloxistat is glycolate oxidase inhibitor, used to inhibit hyperoxaluria and kidney stones.
    Vamagloxistat
  • HY-156662
    Casein kinase 1δ-IN-7 764694-25-9
    Casein kinase 1δ-IN-7 (compound 497) is a Casein kinase 1δ inhibitor. Casein kinase 1δ-IN-7 can be used in the study of neurodegenerative disorders such as Alzheimer's disease.
    Casein kinase 1δ-IN-7
  • HY-156868
    22-Hydroxyvitamin D3 110927-46-3 98%
    22-Hydroxyvitamin D3 a novel vitamin D analog, that displays no vitamin D agonist activity in the intestine or in bone.
    22-Hydroxyvitamin D3
  • HY-156965
    BAY-771 2771756-82-0 98%
    BAY-771, a structurally close pyrimidinedione, is a chemical probe with good lead-like properties and high permeability in Caco-2 cells (no hint of efflux). BAY-771 shows very weak inhibitory activity in the BCAT1 biochemical assay and no activity in BCAT2. BAY-771 can be used as a negative control of HY-148242 BAY-069. BAY-771 can be used for the research of tumor metabolism.
    BAY-771
  • HY-157124
    Tyrosinase-IN-19 98%
    Tyrosinase-IN-19 (compound 9) is a competitive tyrosinase inhibitor. Tyrosinase-IN-19 has strong antioxidant activities against ROS, ABTS+, and DPPH radicals. Tyrosinase-IN-19 suppresses tyrosinase expression in a dose-dependent manner.
    Tyrosinase-IN-19
  • HY-157127
    Ketoprofen L-thyroxine ester 3032398-41-4 98%
    Ketoprofen L-thyroxine ester is a prodrug of Ketoprofen. Ketoprofen L-thyroxine ester reservoir and release ketoprofen slowly in the brain.
    Ketoprofen L-thyroxine ester
  • HY-157225
    Brazilin-7-acetate 3040318-36-0 98%
    Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease.
    Brazilin-7-acetate
  • HY-157312
    TM38837 1034264-77-1 98%
    TM38837 is an orally active and selective inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 24 nM. TM38837 has higher selectivity for CB1 than for CB2 (IC50: 4500 nM). TM38837 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis.
    TM38837
  • HY-157390
    DPP-4-IN-9 2906243-39-6 98%
    DPP-4-IN-9 (compound 6l) is a potent inhibitor of dipeptidyl peptidase DPP-4 (IC50: 8.22 nM). DPP-4-IN-9 has antihyperglycemic activity.
    DPP-4-IN-9
  • HY-157445
    CBR1-IN-3 891101-69-2 98%
    CBR1-IN-3 (compound 13h) is a potent inhibitor of carbonyl reductase 1 (CBR1), with IC50 value of 0.034 μM.
    CBR1-IN-3
  • HY-157457
    Z21090 2992690-71-6 98%
    Z21090 (ZL40) is a potent inhibitor of PDE4 with the IC50 value of 37.4 nM and oral bioavailability. Z21090 plays an important role in alcohol-related diseases research.
    Z21090
Cat. No. Product Name / Synonyms Application Reactivity